2006, Cannabinoids, DEA and Epilepsy - Medical Cannabis Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2006

Cannabinoids

DEA

Epilepsy

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). 1 Simultaneously, the AAFP acknowledges preliminary evidence indicates marijuana and cannabinoids may have potential therapeutic benefits, while also recognizing subsequent negative public health and health outcomes associated with cannabis use.

Cannabinoids

Cannabinoids Marijuana Research and Development Access

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction

Extraction Pharmaceutical CBD Epilepsy

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Stay Connected